EICHORCondition: Autosomal Dominant Hypocalcemia (ADH) · Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company
The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| UCSF Benioff Children's Hospital, Oakland | Oakland, California, United States | — |
| Children's Hospital Colorado | Aurora, Colorado, United States | — |
| Indiana University Health University Hospital | Indianapolis, Indiana, United States | — |
| NIH | Bethesda, Maryland, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Mayo Clinic - Rochester | Rochester, Minnesota, United States | — |
| Columbia University Irving Medical Center | New York, New York, United States | — |
| Physicians East | Greenville, North Carolina, United States | — |
| Ohio State University Medical Center | Columbus, Ohio, United States | — |
| The Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | — |
| Houston Methodist Hospital | Houston, Texas, United States | — |
| Royal North Shore Hospital | Saint Leonards, New South Wales, Australia | — |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05680818